Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company's product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Life Sciences Tools & Services
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:FURX
- CUSIP: 36106P10
- Web: N/A
- Trailing P/E Ratio:
- Foreward P/E Ratio: 99.78
- P/E Growth:
Frequently Asked Questions for Furiex Pharmaceuticals (NASDAQ:FURX)
What is Furiex Pharmaceuticals' stock symbol?
Furiex Pharmaceuticals trades on the NASDAQ under the ticker symbol "FURX."
Who are some of Furiex Pharmaceuticals' key competitors?
Some companies that are related to Furiex Pharmaceuticals include Merck KGaA (MKGAY), Hospira (HSP), Omnicare (OCR), Health Net (HNT), WuXi PharmaTech (Cayman) (WX), Hanger (HGR), SIGA Technologies (SIGA), Nobilis Health Corp (HLTH), Verastem (VSTM), Palatin Technologies (PTN), KaloBios Pharmaceuticals (KBIO), AdCare Health Systems (ADK), Capricor Therapeutics (CAPR), 3SBio (SSRX), Alexza Pharmaceuticals (ALXA), Allergan plc (WPI), Allergan plc (ACT) and Allos Therapeutics (ALTH).
How do I buy Furiex Pharmaceuticals stock?
Shares of Furiex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Furiex Pharmaceuticals' stock price today?
MarketBeat Community Rating for Furiex Pharmaceuticals (NASDAQ FURX)MarketBeat's community ratings are surveys of what our community members think about Furiex Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Furiex Pharmaceuticals stock can currently be purchased for approximately $104.77.
Consensus Ratings for Furiex Pharmaceuticals (NASDAQ:FURX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Furiex Pharmaceuticals (NASDAQ:FURX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Furiex Pharmaceuticals (NASDAQ:FURX)Earnings History by Quarter for Furiex Pharmaceuticals (NASDAQ FURX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/7/2014||Q114||($0.63)||($1.25)||$10.01 million||$6.40 million||View||N/A|
|3/11/2014||Q413||($1.06)||($0.63)||$12.80 million||$13.10 million||View||N/A|
|8/6/2013||Q2 2013||($1.65)||($2.32)||$11.94 million||$3.00 million||View||N/A|
|5/7/2013||Q1 2013||$0.70||$0.82||$33.42 million||$39.33 million||View||N/A|
|3/6/2013||Q4 2012||($2.04)||($0.90)||$7.43 million||$9.21 billion||View||N/A|
Earnings Estimates for Furiex Pharmaceuticals (NASDAQ:FURX)
Current Year EPS Consensus Estimate: $-2.27 EPS
Next Year EPS Consensus Estimate: $1.05 EPS
Dividend History for Furiex Pharmaceuticals (NASDAQ:FURX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Furiex Pharmaceuticals (NASDAQ:FURX)Insider Trades by Quarter for Furiex Pharmaceuticals (NASDAQ:FURX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/24/2014||Paul S Covington||VP||Sell||10,368||$104.12||$1,079,516.16|| |
|6/24/2014||Sailash Patel||CFO||Sell||32,928||$104.00||$3,424,512.00|| |
|6/18/2014||Paul S Covington||VP||Sell||45,691||$104.11||$4,756,890.01|| |
|6/17/2014||Gail Frances Mcintyre||SVP||Sell||74,457||$105.01||$7,818,729.57|| |
|6/13/2014||Paul S Covington||VP||Sell||3,228||$104.25||$336,519.00|| |
|6/10/2014||Gail Frances Mcintyre||SVP||Sell||1,746||$104.58||$182,596.68|| |
|6/10/2014||Paul S Covington||VP||Sell||2,872||$104.63||$300,497.36|| |
|6/10/2014||Sailash Patel||CFO||Sell||1,504||$104.68||$157,438.72|| |
|9/10/2013||Paul S Covington||VP||Sell||30,000||$40.89||$1,226,700.00|| |
|8/9/2013||Peter Corr||Director||Sell||7,500||$39.74||$298,050.00|| |
|7/19/2013||Gail Frances Mcintyre||SVP||Sell||10,581||$40.00||$423,240.00|| |
|3/12/2013||Stephen W Kaldor||Director||Sell||6,352||$41.58||$264,116.16|| |
|8/15/2012||June Sherie Almenoff||President||Buy||1,000||$18.67||$18,670.00|| |
Headline Trends for Furiex Pharmaceuticals (NASDAQ:FURX)
Latest Headlines for Furiex Pharmaceuticals (NASDAQ:FURX)
No headlines for this company have been tracked by MarketBeat.com
Furiex Pharmaceuticals (FURX) Chart for Monday, May, 29, 2017